StockNews.AI
ADMA
StockNews.AI
175 days

ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

1. ADMA announced its Q4 and full year 2024 earnings release date. The conference call is scheduled for March 3, 2025. 2. Investors can join via dial-in and live webcast. Details and archived replay are available on the company website. 3. The announcement reiterates ADMA’s focus on manufacturing specialty biologics. This update prepares the market for forthcoming earnings data.

Earnings
+1.77%Current Return
VS
-0.66%S&P 500
$15.5202/25 07:22 AM EDTEvent Start
$15.79502/26 01:51 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Neutral?

The announcement is an earnings preview with no forward guidance or surprises. Historically, such scheduled calls have not shifted prices until results are released.

How important is it?

Earnings announcements can result in significant short-term price movement. However, without new operational updates, the fundamental outlook remains unchanged.

Why Short Term?

Earnings reports typically drive near-term volatility. Similar events in the past have led to immediate price adjustments post-release.

Related Companies

Conference Call Scheduled for March 3, 2025, at 4:30 p.m. ET February 25, 2025 07:00 ET  | Source: ADMA Biologics, Inc. RAMSEY, N.J. and BOCA RATON, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report fourth quarter and full year 2024 financial results on March 3, 2025, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call, please dial (888) 596-4144 and refer to conference ID 5201334. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts. About ADMA Biologics, Inc. (ADMA) ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty biologics and human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com. INVESTOR RELATIONS CONTACT:Argot Partners | 212-600-1902 | ADMA@argotpartners.com

Related News